 Neither clients are blind nor clinicians are blind. And that's just really, really problematic for a clinical trial. It doesn't really allow for valid inferences, which is why I wasn't surprised FDA advisory committee voted pretty strongly against MAPS having shown efficacy for their treatment suggestion.